Free shipping on orders over $200
Free shipping on orders over $200
Molecular Weight
Purity
Storage
Appearance
Solubility
01
This three-component reference material combines two GHRH-receptor agonists and one ghrelin-receptor agonist. Tesamorelin is a full-length GHRH(1–44) analogue with an N-terminal acyl cap; CJC-1295 (No DAC) is a 29-residue GHRH fragment stabilised by four amino acid substitutions; Ipamorelin is a small, selective ghrelin-receptor (GHS-R1a) agonist.
The blend therefore covers both receptor pathways of the growth hormone axis, and includes two structurally different ligands for the same GHRH receptor. It is used as a standard sample for multi-analyte analytical methods, co-formulation stability work and in vitro studies of combined receptor activation. Each component is described in full on its own reference page. This blend is supplied as a lyophilized reference material for in vitro research only.
02
The three components span roughly 0.7 to 5.1 kDa and fall into two receptor classes.
Tesamorelin (5135.9 g/mol, 44 residues)
The complete GHRH sequence protected by a trans-3-hexenoyl group on Tyr1. It keeps the native Met27 and is the only component in the blend with a methionine.
CJC-1295 No DAC (3367.9 g/mol, 29 residues)
The GHRH(1–29) fragment with D-Ala2, Gln8, Ala15 and Leu27. Swapping Met27 for Leu removes its oxidation risk, and it carries no albumin-binding linker.
Ipamorelin (711.85 g/mol, 5 residues)
A compact peptide with Aib, D-2-naphthylalanine and D-phenylalanine, making it resistant to proteases and strongly UV-absorbing.
The clear differences in size and hydrophobicity allow each component to be separated and measured individually.
03
The blend gives access to both receptor systems that control growth hormone release.
Two GHRH-receptor ligands
Tesamorelin and CJC-1295 No DAC both activate the Gs-coupled GHRH receptor (cAMP signalling) but differ in length and in how they are protected from degradation, which is useful for comparative studies.
Ghrelin-receptor pathway
Ipamorelin activates the Gq-coupled GHS-R1a, which signals through phospholipase C, IP₃ and calcium release, a route independent of cAMP.
Combined activation
In pituitary cell preparations, the blend allows comparison of single, dual and triple application to examine how the two pathways interact.
Co-formulation behaviour
Stability studies check whether the three peptides affect one another’s recovery or degradation in the dried or reconstituted state.
All research context described here refers to controlled in vitro experimental systems.
04
Three-component HPLC methods
A demanding test sample for methods that must resolve and quantify three peptides of very different sizes in a single run.
System suitability and calibration
Provides three well-spaced molecular weights in one injection, useful for checking HPLC and LC-MS performance across a wide mass range.
Co-formulation stability
Used in accelerated storage studies to see whether blending changes the degradation of any component, especially Met27 oxidation in Tesamorelin.
Receptor pharmacology
A standardised mixed-agonist preparation for comparing combined and single-agent activation in pituitary cell models.
05
Storage
Store the sealed vial at −20 °C, desiccated and protected from light. Let it reach room temperature before opening.
Reconstitution
All three components are water-soluble. Dissolve in water or a near-neutral aqueous buffer with gentle swirling; avoid vigorous shaking.
Oxidation
Tesamorelin’s Met27 is the main oxidation-sensitive site in the blend (CJC-1295 No DAC has leucine at this position). Minimise light and air exposure and avoid peroxide-containing reagents.
Solutions
Divide into single-use aliquots after reconstitution and freeze; avoid repeated freeze–thaw cycles. Use low-binding polypropylene labware.
06
Each component is identified and quantified separately within the mixture.
HPLC
Reversed-phase C18 with an acetonitrile/water gradient resolves the three components. Detection at 214 nm covers all three; 280 nm adds selectivity for aromatic residues. Retention order depends on the column and gradient, so it is established with individual standards.
Mass spectrometry
Ipamorelin appears as [M+H]⁺ at m/z 712.4; CJC-1295 No DAC mainly at +3 to +5 (about m/z 675–1124); Tesamorelin at +4 to +8 (about m/z 643–1285). Accurate masses distinguish the charge-state series.
Component ratio
The ratio is confirmed by peak areas calibrated against each component’s own reference standard, or normalised using calculated extinction coefficients.
Purity
Each component is assessed against its own specification, including Tesamorelin oxidation, CJC-1295 D-Ala2 configuration and Ipamorelin epimers.
07
Three peptides: Tesamorelin and CJC-1295 (No DAC), both GHRH-receptor agonists, and Ipamorelin, a ghrelin-receptor agonist. The amount of each component is stated on the product label and certificate of analysis.
Tesamorelin and CJC-1295 No DAC reach the same receptor with different designs, a full-length acyl-capped sequence versus a substituted 29-residue fragment, which allows their behaviour to be compared within one material.
Tesamorelin, because it keeps the native Met27. CJC-1295 No DAC has leucine at that position and Ipamorelin contains no methionine.
Reversed-phase HPLC separates them, and each peak is quantified against its own reference standard. Mass spectrometry confirms each identity through its own charge-state pattern.
No. It is supplied strictly as a reference material for laboratory and analytical research and is not for human or animal use.
Tesamorelin + Ipamorelin + CJC-1295 (No DAC) Blend Research Reference. (2026). Pure Peptides Labs Research Catalogue. Retrieved from https://purepeptideslabs.net/research-catalogue/growth-hormone-axis-research-peptides/tesamorelin-ipamorelin-cjc-1295-blend/
Materials listed on this platform are supported by independent testing and published documentation for laboratory research contexts.
